Advertisement
RVTY or TMO or WAT
Which Stock Would AI Choose? Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) vs. Waters (WAT) Stock Comparison
Key Takeaways
- TMO boasts the largest market capitalization at $174 billion and reported strong Q1 2026 revenue growth of 6% to $11.01 billion, outperforming analyst estimates.
- WAT and TMO lead year-to-date (YTD) performance with gains around 19%, while RVTY trails at 10%.
- TMO trades at the lowest price-to-earnings (P/E) ratio of 25.77 among the trio, suggesting relative value compared to RVTY's 42.08 and WAT's 28.57.
- Recent weeks have seen mixed momentum: TMO dipped post-earnings despite beats, while RVTY and WAT face upcoming Q1 earnings on May 5.
- All three operate in life sciences instruments, benefiting from biopharma demand but exposed to macroeconomic pressures.
Introduction
This stock comparison examines RVTY, TMO, and WAT, key players in scientific instruments and life sciences solutions. These companies provide analytical tools, diagnostics, and research equipment essential for pharmaceuticals, biotech, and academia. Traders seeking sector exposure and investors tracking relative performance in a volatile market will find value here. With recent earnings cycles highlighting growth divergences and upcoming reports for two firms, this analysis aids in understanding current market positioning, momentum shifts, and valuation contrasts amid broader healthcare trends.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY) focuses on life sciences solutions, including diagnostics, drug discovery tools, and health science technologies. In recent market activity, the stock has traded around $86.68, reflecting YTD gains of 10.28% but pressure from mixed returns and a 52-week range of $81.22 to $118.30. Sentiment has been influenced by Q4 2025 earnings beats, with adjusted EPS of $1.70 surpassing estimates, and positive 2026 guidance above consensus. However, scrutiny over declining revenues and high valuations has weighed on shares, alongside a recent dividend declaration and shareholder approvals. Upcoming Q1 2026 results on May 5 could shift dynamics, amid ongoing product launches like Signals BioDesign.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a global leader in life sciences tools, serving research, diagnostics, and biopharma with instruments and services. Shares recently closed at $469.21, up 18.94% YTD within a 52-week range of $385.46 to $643.99. Recent weeks featured robust Q1 2026 results, with revenue of $11.01 billion (up 6%) and adjusted EPS of $5.44 beating forecasts, though shares dipped on organic growth concerns. Strategic moves, including a $1 billion microbiology unit sale and a new bioprocess center, bolster sentiment. Dividend hikes and investor interest underscore stability in a challenging environment.
WAT Overview and Recent Performance
Waters Corporation (WAT) specializes in analytical instruments like chromatography and mass spectrometry for pharma and research. The stock hovers near $307.12, with 19.14% YTD returns in a 52-week span of $275.05 to $414.15. Recent performance shows a 19% decline over 90 days, tied to softer organic growth, despite Q4 2025 sales up 7% to $3.165 billion overall. Market sentiment reflects caution on margins, but optimism builds ahead of Q1 2026 earnings on May 5, with expected EPS growth. Analyst adjustments and sector tailwinds support positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page curates 25 top-performing AI trading bots from over 351 available, each scanning thousands of tickers for real-time signals suited to current conditions like AI infrastructure and semis booms. These bots showcase win rates from 51% to 88%, annualized returns of +23% to +163%, profit factors up to 11.70, and drawdowns managed via strategies like TP/SL corridors over timeframes from 5 minutes to 49 days. Diverse styles—swing, scalping, multi-agent—adapt to volatility, often outperforming the S&P 500. Explore these for automated insights across sectors; check the page to copy trade the trending performers today.
Head-to-Head Comparison
RVTY, TMO, and WAT share business models centered on precision instruments for life sciences, but TMO’s scale offers broader diversification via services and consumables. Growth drivers include biopharma R&D demand, though all face macro risks like China slowdowns. Recent momentum favors TMO post-earnings beat, contrasting WAT’s 90-day dip and RVTY’s valuation concerns. TMO exhibits lower P/E sensitivity, while smaller peers show higher volatility. Sector exposure is similar, but sentiment tilts toward TMO’s stability versus growth trade-offs in RVTY and WAT.
Tickeron AI Verdict
Tickeron’s AI currently leans toward TMO based on trend consistency from recent earnings beats, superior scale, and relative valuation. Its stability and catalysts like bioprocess expansions position it favorably amid sector pressures, though WAT and RVTY earnings could alter dynamics. This probabilistic edge reflects observable momentum, not guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 3 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s), and WAT’s FA Score reflects 1 green FA rating(s).
- RVTY’s FA Score: 3 green, 2 red.
- TMO’s FA Score: 1 green, 4 red.
- WAT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 5 bullish TA indicator(s), and WAT’s TA Score reflects 3 bullish TA indicator(s).
- RVTY’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 5 bullish, 5 bearish.
- WAT’s TA Score: 3 bullish, 5 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а +13.02% price change this week, while TMO (@Medical Specialties) price change was +10.42% , and WAT (@Medical Specialties) price fluctuated +5.34% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +8.88%. For the same industry, the average monthly price growth was +11.83%, and the average quarterly price growth was +6.31%.
Reported Earning Dates
RVTY is expected to report earnings on Aug 03, 2026.
TMO is expected to report earnings on Jul 29, 2026.
WAT is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (+8.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| RVTY | TMO | WAT | |
| Capitalization | 12.6B | 191B | 36.8B |
| EBITDA | 773M | 11.7B | 991M |
| Gain YTD | 16.979 | -11.286 | -1.427 |
| P/E Ratio | 47.62 | 25.51 | 45.58 |
| Revenue | 2.9B | 45.2B | 3.77B |
| Total Cash | 860M | 1.12B | 462M |
| Total Debt | 3.35B | 43.2B | 5.57B |
RVTY | TMO | WAT | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 87 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 13 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | 81 | |
SMR RATING 1..100 | 89 | 62 | 85 | |
PRICE GROWTH RATING 1..100 | 13 | 48 | 45 | |
P/E GROWTH RATING 1..100 | 33 | 43 | 21 | |
SEASONALITY SCORE 1..100 | n/a | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is in the same range as RVTY (15) and is somewhat better than the same rating for WAT (73). This means that TMO's stock grew similarly to RVTY’s and somewhat faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (81) in the Medical Specialties industry is in the same range as TMO (86) and is in the same range as RVTY (100). This means that WAT's stock grew similarly to TMO’s and similarly to RVTY’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as WAT (85) and is in the same range as RVTY (89). This means that TMO's stock grew similarly to WAT’s and similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (13) in the Medical Specialties industry is in the same range as WAT (45) and is somewhat better than the same rating for TMO (48). This means that RVTY's stock grew similarly to WAT’s and somewhat faster than TMO’s over the last 12 months.
WAT's P/E Growth Rating (21) in the Medical Specialties industry is in the same range as RVTY (33) and is in the same range as TMO (43). This means that WAT's stock grew similarly to RVTY’s and similarly to TMO’s over the last 12 months.
| RVTY | TMO | WAT | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 1 day ago 55% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 60% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 59% | 1 day ago 58% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 67% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 61% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 61% | 1 day ago 61% |
| Advances ODDS (%) | 3 days ago 65% | 1 day ago 61% | 3 days ago 64% |
| Declines ODDS (%) | 26 days ago 67% | 16 days ago 63% | 10 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 60% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 49% | 1 day ago 56% | 1 day ago 55% |
Advertisement
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -0.66% | ||
| A - WAT | 67% Closely correlated | +0.37% | ||
| RVTY - WAT | 63% Loosely correlated | -0.45% | ||
| TMO - WAT | 59% Loosely correlated | +1.44% | ||
| BRKR - WAT | 58% Loosely correlated | +0.03% | ||
| RGEN - WAT | 56% Loosely correlated | +1.20% | ||
More | ||||